Quality-of-life assessment in rheumatoid arthritis.
Rheumatoid arthritis (RA) is a chronic and lifelong autoimmune disorder that results in significant pain, disability and excess mortality if untreated or inadequately treated. Quality-of-life (QOL) assessments are particularly important in the absence of a cure for RA. Generic and disease-specific patient-reported QOL instruments, such as the Health Assessment Questionnaire (HAQ) Disability Index and the SF-36, have proven validity and sensitivity for assessment of changes in QOL in clinical trials of disease-modifying anti-rheumatic drugs (DMARDs). However, these instruments are rarely utilized in clinical practice, and patients have reported that the actual clinical assessments alone do not address important parameters, such as fatigue and disturbed sleep, which significantly affect QOL.New biological DMARDs have shown significant efficacy in improving clinical and QOL parameters in randomized controlled trials. However, the high cost of biological DMARDs compared with non-biological DMARDs is a factor in the increasing health costs associated with the treatment of RA. Generic health utility instruments that measure QOL parameters enable calculation of the increased QALYs associated with more costly treatment in patients with RA. The costs per QALY associated with biological DMARDs in RA appear to be comparable to those of other accepted medical interventions. Interest in incorporating QOL parameters in formulary and public health decision making concerning the use of new agents for RA is increasing.
Russell
Anthony S
AS
Rheumatic Disease Unit, Heritage Medical Research Centre, University of Alberta, Edmonton, Alberta, Canada. as.russell@ualberta.ca
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D002986:Clinical Trials as Topic; D006305:Health Status Indicators; D006801:Humans; D011788:Quality of Life; D011795:Surveys and Questionnaires
D018501:Antirheumatic Agents
Qual Life Res. 2005 Mar;14(2):285-95
15892420
Health Policy. 1996 Jul;37(1):53-72
10158943
Semin Oncol. 2002 Feb;29(1S2):2-9
28140087
Ann Rheum Dis. 2002 Nov;61(11):986-93
12379521
Med Care. 2003 Jul;41(7):791-801
12835603
Mayo Clin Proc. 2002 Apr;77(4):371-83
11936935
Adv Ther. 2006 Mar-Apr;23(2):208-17
16751154
J Rheumatol. 2006 Apr;33(4):665-70
16568506
Rheumatology (Oxford). 2006 Oct;45(10):1238-46
16567357
J Rheumatol. 1993 Mar;20(3):557-60
8478873
Expert Opin Drug Saf. 2005 Mar;4(2):149-55
15794709
Drugs. 2005;65(4):473-96
15733011
Arthritis Rheum. 1995 Jun;38(6):727-35
7779114
Rheumatol Int. 2006 May;26(7):655-62
16184384
Rheumatology (Oxford). 2004 Jun;43(6):712-8
15039494
Arthritis Rheum. 1980 Feb;23(2):137-45
7362664
Rheumatology (Oxford). 2000 Jun;39 Suppl 1:17-23
11001375
Am J Manag Care. 2002 Sep;8(9):811-20
12234022
J Rheumatol. 2002 Jan;29(1):62-7
11824973
J Gen Intern Med. 1994 Oct;9(10):576-82
7823230
Arthritis Rheum. 2005 Aug;52(8):2263-71
16052582
Rheumatol Int. 2007 May;27(7):661-6
17195065
Arthritis Rheum. 2004 Apr;50(4):1051-65
15077287
Rheumatology (Oxford). 2006 Jan;45(1):66-71
16263782
Med Care. 1993 Mar;31(3):247-63
8450681
Arthritis Rheum. 2000 Oct;43(10):2316-27
11037892
Best Pract Res Clin Rheumatol. 2006 Oct;20(5):849-63
16980210
Rheumatology (Oxford). 2002 Jun;41(6):638-42
12048289
Control Clin Trials. 1989 Dec;10(4):407-15
2691207
Med Care. 2004 Nov;42(11):1125-31
15586840
J Rheumatol. 2006 Apr;33(4):681-9
16568505
Pharmacoeconomics. 2000 Jan;17(1):13-35
10747763
Rheumatology (Oxford). 2003 May;42 Suppl 2:ii22-8
12817092
Soc Sci Med. 1995 Nov;41(10):1403-9
8560308
J Rheumatol. 2003 May;30(5):941-7
12734886
Rheumatology (Oxford). 2006 Sep;45(9):1121-4
16510526
N Engl J Med. 2005 Sep 15;353(11):1114-23
16162882
Arthritis Rheum. 2002 Feb;46(2):328-46
11840435
Arthritis Rheum. 2003 Aug 15;49(4):574-84
12910566
Arthritis Rheum. 1992 Jan;35(1):1-10
1731806
Br J Rheumatol. 1997 Aug;36(8):878-83
9291857
Med Care. 1992 Jun;30(6):473-83
1593914
Pharmacoeconomics. 1994 Dec;6(6):513-22
10155281
J Manag Care Pharm. 2006 Sep;12(7):555-69
16981801
J Gen Intern Med. 1998 Oct;13(10):664-9
9798812
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S65-70
15552517
J Health Econ. 2002 Mar;21(2):271-92
11939242
Ann Rheum Dis. 2007 Feb;66(2):189-94
16984942
Arthritis Rheum. 2000 Jul;43(7):1478-87
10902749
Arthritis Rheum. 2006 Sep;54(9):2793-806
16947627
J Rheumatol. 2003 Apr;30(4):886-90
12672223
Am J Manag Care. 2002 Mar;8(3):231-40
11915973
Curr Opin Rheumatol. 2002 Mar;14(2):121-6
11845016
Health Policy. 1990 Dec;16(3):199-208
10109801
Pharmacoeconomics. 2002;20(7):463-73
12093302
J Rheumatol. 1997 Sep;24(9):1697-702
9292790
Postgrad Med. 1998 Feb;103(2):103-6, 110, 116-8 passim
9479310
Health Qual Life Outcomes. 2003 Oct 16;1:54
14613568
Health Qual Life Outcomes. 2003 Jun 09;1:20
12831398
Pharmacoeconomics. 2004;22(2 Suppl 1):27-38
15157002
Arthritis Rheum. 2006 Feb;54(2):613-20
16447239
Expert Rev Pharmacoecon Outcomes Res. 2005 Aug;5(4):395-410
19807258
J Rheumatol. 2003 Apr;30(4):639-41
12672177
Scand J Rheumatol. 2005 Sep-Oct;34(5):333-41
16234180
Rheumatology (Oxford). 2007 Apr;46(4):626-30
17189244
Ann Rheum Dis. 2006 Mar;65(3):328-34
16079172
Arthritis Res Ther. 2007;9(5):R103
17922913
Rheumatol Int. 2003 Jan;23(1):21-6
12548438
Med Care. 2002 Feb;40(2):113-28
11802084